A 45-year-old woman had been dialyzed for 3 years for end-stage renal disease secondary to polycystic kidney disease. She had received two transfusions and had developed antibodies reacting with 20% of the local screening panel. The patient was offered renal transplantation and agreed to enroll in a randomized study to evaluate the efficacy of a monoclonal antibody (mAb), directed against an adhesion/co-stimulatory molecule, CDIIa, in improving graft survival. In this study, the antibody, which had yielded encouraging results in a recent pilot study, was compared (in an induction protocol) with anti-thymocyte polyclonal globulins. The protocol called for the monoclonal antibody to be administered at 20 mg/day for 10 days, along with 1 mg/kg of steroids (tapered every week, until complete withdrawal at day 45) and 2.5 mg/kg of azathioprine; cyclosporine A (C5A) was begun at the end of the mAb administration. At day 2 post transplantation, the patient excreted 2 liters of urine; her serum creatinine level decreased progressively to levels below 150 j.M (1.6 mg/dl) at day 9. No adverse effect of the mAb was noted. Circulating trough levels reached 7 jsg/ml at day 6 and peaked at 11 jig/mI at day 11. No changes in white blood cell counts were noted after an initial decline of 20% in lymphocyte count. As early as day 3, LFA-1 site occupancy of the patient's lymphocytes by the antibody was saturated. In addition, patient-activated T-cells had lost their capacity to bind a B-cell line bearing ICAM-1, the ligand of LFA-1. An almost total modulation of the patient's CD11a molecule at the lymphocyte surface membrane was found at the end of the treatment. All these biologic effects disappeared by day 30.
Anti-lymphocyte reagents used in allograft transplantation were first confined to rabbit anti-lymphocyte polyclonal gamma globulins (ALG) [2] , but now a growing family of potentially useful monoclonal antibodies (mAbs) is available that recognizes a variety of targets not solely on lymphocytes. The diversity of this group of antibodies depends only on our knowledge of molecular interactions at the immunocompetent cell surface. Although well recognized as being effective in preventing and treating rejection, ALG is associated with several disadvantages. These include variability among batches, broad reactivity with antigens unrelated to lymphocytes, and the occurrence of serum sickness. Therapy with carefully selected monoclonal antibodies should circumvent these problems, as mAbs have a single defined specificity, a unique target, and are used at low dosage, thus virtually eliminating serum sickness. In addition, their effectiveness usually can be followed through specific monitoring, as exemplified in the patient presented and in Figure 1 . The use of bioreagents in rejection prophylaxis protocols is of primary importance in preventing the recipient immune response during the first weeks after transplantation. In renal transplantation, this approach allows the initiation of cyclosporine A to be delayed until stable graft function is obtained, with control of the immune response by the mAb at the time of maximal risk of rejection. This approach usually is associated with better functional results, increased patient comfort, and shorter hospitalization time [3] . However, a higher Fig. 1 . Example of the monitoring of the effect of an anti-CD11a in a human. Besides basic pharmacodynamic information obtained from the measurement of the monoclonal antibody trough levels (U), other information specifically related to the specificity of the mAb and the function of the molecules recognized can be studied, for instance, inhibition of T-B cell adhesion (L) and CD11a site occupancy (•). rejection, as has been demonstrated for an anti-IL2R and an anti-CD11a mAb [5, 6] .
To date, only Orthoclone OKT3 (OKT3) has been used on a large scale in the treatment (and later, prevention) of rejection in human allograft recipients [7] . Many other monoclonal antibodies directed at several different surface membrane molecules involved in immune recognition are being actively explored in experimental animals, and some of them are under study in pilot or randomized clinical trials. In this Forum, I will focus on the mAbs already used in the treatment of human allograft recipients. I also will briefly discuss the new possibilities offered by some mAbs still under study in animal models, as well as the new therapeutic tools derived from monoclonal antibodies that have emerged from molecular biologic techniques, such as chimeric or humanized mAbs, or fusion molecules that comprise a part of the immunogloblin (Ig) structure.
Rationale for the choice of potential targets Experimental data in animals indicate that therapeutic options can vary according to the type of organ transplanted, the class Ior class-Il compatibilities, and the magnitude of immunosuppression required by the clinical situation (for example, preimmunization). Therefore, different reagents are required to exert various effects on the recipient's immune response and to act at different steps.
Murine IgG monoclonal antibodies have poor and sometimes undemonstrated in-vitro effector functions such as complementdependent killing, antibody-dependent cytotoxicity, and opsonization. Thus, antibodies directed at "functional" surface-membrane molecules have been preferred to those recognizing "structural" targets, for example, anti CD7 [8] [9] [10] [11] , T12 or CD6 [12] , or CBL1 antibodies [13] , not primarily involved in immune recognition or effector functions of immunocompetent cells. Furthermore, some antibodies, highly specific for a function, by interacting with a minority of immunocompetent cells, might gain in specificity and produce fewer side effects by delivering inhibitory signals only, without destroying their target ( Table 1 ). The interpretation of these data has been complicated by the observation that some mAbs could induce tolerance rather than classic immunosuppression. Although this concept is extremely attractive, the salutary state of tolerance has been achieved only in rodent allografts. In this model, the tolerance state, as defined by a long-term acceptance of donor tissues with rejection of third-party tissues can, however, be produced by different immune manipulations, including pregraft donor blood transfusions [14] , administration of CsA [15] , anti-ICAM/LFA-l [16] , anti-CD4 mAbs [17] , and may result from efficient early immunosuppresion rather than from a specific effect of the mAbs used.
Our ability to employ specific mAbs in vivo in animal models and in some clinical trials is governed by our current knowledge in the field of immune recognition and effector functions, especially our understanding of the T-cell receptor complex, the growth factor receptor involved in the clonal expansion of committed cells, and adhesion and "second signal" molecules. These various target families respond to different stimuli and have various molecular interaction requirements; in some instances, the mAb acts directly by modulating a ligand at the cell membrane (for example, anti-CD3), whereas others act mostly as competitors for soluble (for example, anti-IL2R) or membranous ligands (for example, anti-LFA-1, anti-ICAM-1). In the last examples, the epitope recognized is of paramount importance in achieving a high degree of functional inhibition. The search for important targets is not over and we are still in a phase of exploring potentially interesting reagents (Fig. 2 ). [19] and marketed in 1986, OKT3 is now widely recognized as a powerful immunosuppressive agent that reverses acute rejection [20] and is as effective as ALG in protocols designed to achieve prophylaxis [21] . In these studies [19, 20] , OKT3 was given intravenously at a daily dose of 5 mg for 10 to 14 days, but lower doses (such as 22 mg over 10 days) have yielded good results in induction protocols of renal transplantation [22] . Whereas high doses of steroids reversed 75% of acute renal rejection episodes [7] , OKT3 reversed 94% of acute rejection episodes; OKT3 also was effective in rejection episodes resistant to steroids or ALG [23] . The effect of OKT3 on renal function is somewhat delayed, however, occurring within 20 days after the Onset of the treatment, and even longer in the case of steroid-or ALG-resistant rejection episodes [22] . Recurrent rejection episodes occur frequently (66% of patients) when OKT3 is administered without CsA [7] but only in 33% of patients given
In protocols designed for prophylaxis, cardiac transplant recipients treated with OKT3 experienced fewer acute rejection episodes during the first 3 months post transplantation than did those treated with ALG (1,5 0.2 versus 2.2 0.2 rejection episodes per patient) and required less chronic maintenance immunosuppression [25] . A randomized prospective trial in renal transplantation showed that OKT3 and ALG produced similar results [26] .
The OKT3 monoclonal antibodies interact only with T-lymphocytes and therefore are more specific than ALGs, which also bind to monocytic, natural killer (NK) and B cells. In vitro, OKT3 inhibits both the generation of functional effector T-cells and the activity of mature cytotoxic effector lymphocytes [27] . Peripheral blood lymphocyte counts drop dramatically, but transiently, after OKT3 administration, and reappearing T-lymphocytes fail to express CD3 or T-cell receptors, whereas the other T-cell surface determinants are normally expressed [28] . This modulation is rapidly reversible after cessation of OKT3 or when patients are immunized against the mAb. Accordingly, monitoring of OKT3 treatment can be based on measurement of the magnitude of the decrease of the ratio of CD37CD2 circulating cells and, to a lesser extent, on the measurement of the OKT3 plasma levels, even though levels of 1 g/ml correspond to a concentration that blocks T-cell functions in vitro. But OKT3 administration at the usual doses does not always completely eliminate CD3 cells in the graft [29] , and changes in the local T-lymphocyte populations, with a shift toward an increase in CD8 and 2H4 cells, have been reported [30] .
The major problem associated with OKT3 is that severe adverse side effects occur in a majority of patients, starting 45 to 60 minutes after the first two or three OKT3 injections and lasting for several hours. These sequelae can include OKT3-mediated nephrotoxicity, with an average increase of 31% in serum creatinine levels before improvement [31] . Pulmonary edema can be prevented if any existing fluid overload is corrected before treatment [7] . These side effects are related to the massive, although Several other monoclonal antibodies directed against CD3 or against T-cell receptor monomorphic epitopes have been tested in human renal transplantation. While these newer anti-CD3 monoclonal antibodies did not significantly reduce cytokine release [43] , progress may come from using mAbs against the monomorphic determinant of a/3 chains of the T-cell receptor [44] , which can reverse acute rejection episodes and yield fewer and less severe side effects than expected. The use of this anti-T-cell receptor monoclonal antibody is associated with an absence of in-vitro mitogenic effect; the antibody does modulate the CD3-T-cell receptor complex at the T-lymphocyte surface. Another anti-a13 chain T-cell receptor mAb (BMA 031, a murine IgG2b) was also studied as prophylaxis but was ineffective at the tested dose [45] .
Another approach uses the F(ab')2 fragments, which neither cause T-cell activation nor increase animal morbidity or mortality, but which prolong the survival of skin allografts [46] reversed graft rejection. Furthermore, an anti-CD1 la associated with an anti-ICAM-1 can induce tolerance in rodents [16] .
Among the adhesion molecules, those of the /32 integrin family, including LFA-1, are involved in the late adhesion process. They are composed of two non-covalently linked polypeptide chains 25-3, also has been used in our center to attempt to reverse first-time acute rejection episodes in 7 recipients of a first-kidney transplant who were taking cyclosporine and azathioprine [6] .
This anti-CD11a mAb, which produced only a few side effects, was not effective in 6 of the 7 patients treated, although circulating levels of mAb 25-3 were at concentrations 3-to 12-fold higher than the mAb dissociation constant (lCd -5 nM); this lack of effectiveness thus was not a consequence of low drug concentration. Interestingly, only one patient of the 7 developed anti-25--3 IgG at day 17, albeit low levels; this observation is consistent with experimental studies [58] . The low incidence of antibodies against mAb 25-3 might be related to the in-vitro ability of anti-CD11a to interfere in the cell-cell interactions leading to antibody production; interference with antibody production could be more sensitive to mAb 25-3 than the cellular events involved in acute rejection. Although attempts at treating acute cellular rejection episodes with anti-CD11a in renal transplantation have been unsuccessful, results obtained in bone marrow transplant recipients suggest that further studies might prove useful, particularly in prophylactic protocols.
Indeed, although inadequate in treating ongoing rejection crisis, the 25-3 anti-CD11 monoclonal antibody has been extremely encouraging when given prophylactically in patients receiving their first renal transplant. In a phase-I study of 15 patients receiving escalating doses (10 to 20 mg/day, administered for the 10 days following transplantation) in the absence of cyclosporine A, we have observed no rejection crisis during the first 30 days [59] . Administration of the anti-CD11a was associated with a full occupancy of the CD11a site, even when used at the lowest dose studied (10 mg/day) and with an impaired adhesiveness of the patient's T-cells for Daudi B cell line (ICAM-1) cells (Fig. 1 ). In addition, disappearance of the bright component of the classical bimodal membrane expression (bright/dim) was found at the end of the treatment, indicating CD11a (as well as CD18) membrane modulation. Only 3 of 15 patients were immunized, and the anti-mouse titers were remarkably low [59] .
A mouse IgG2 antibody directed against one of the three ligands of LFA-1 (ICAM-1), R6.5, also has been tested in kidney and heart transplants; in cynomolgus monkeys, R6.5 delayed and reversed acute interstitial rejection [60] . In this study, the anti-ICAM-1 monoclonal antibody triggered an immune response in the primate and, although the renal endothelial cells of the treated animals were covered by the mAb, graft function was unimpaired and histologic examination did not show vasculitis. The same mAb was recently used in a pilot study in human and hyperimmunized recipients, or in patients having received a kidney with a long ischemia time. Although the number of patients in whom the mAb reached significant circulating levels was low, the incidence of acute rejection (2/7), as well as of delayed graft function, suggests that the interaction with either the receptor or ligand of the LFA-1/ICAM couple prevents allograft rejection [61] . Would the combined use of anti-LFA-1 and anti-ICAM induce a tolerance state, as in the mouse model [16] ?
Despite these promising pilot studies, clinicians fear the potential for severe infection, and only larger trials will allow a more definitive conclusion. Clearly, these extended trials also will have to veri' whether inhibiting the relevant epitope involved in ICAM binding to LFA-1, and therefore its interaction with all of its 3 ligands, will be a better strategy than interfering with ICAM-1, which is only one of the redundant ligands of LFA-1. Theoretically, both anti-LFA-1 and anti-ICAM-1 should equally prevent ischemia-related damage unless a further redundancy of an unknown LFA-1-ligand surrogate exists. A possible effect on delayed function in the anti-CD11a pilot study might have been missed in our trial, owing to the fact that this effect, suggested by the first pilot study with anti-ICAM-1, was noted only in recipients with long ischemia time, whereas short ischemia time was common in our study. Interestingly, a recent report, demonstrating that inhibiting another adhesion molecule (P-selectin) decreases white-blood-cell-related lesions [52}, suggests a need for a deeper exploration of the effect on ischemia-related graft damage of antibodies (or soluble ligands) interacting with various adhesion molecules.
Another potential adhesion/activation target is the CD2. Antibodies have been successfully tested in vivo [53] , and a clinical trial in which anti-CD2 antibodies are associated with anti-CD11a is currently underway in the prevention of mismatched bone- increases LFAI-ICAM interaction [63] . In animals, anti-CD2 mAbs produced cell unresponsiveness and prolonged pancreatic islet grafts (both in naïve and immunized recipients) [64] and cardiac allografts [53] . Furthermore, a combination of an anti-CD2 and anti-CD3 results in the induction of a tolerance state [65] . A fusion protein between LFA3 and the constant part of IgG heavy chain can prolong allograft transplantation in monkeys through a mechanism that involves CD16 cells (Hochman PS, Chisholm P, Marboe CC, et al, unpublished observations). Thus, experimental evidence clearly shows that blockade of the CD2-LFA3 couple is promising in immuno-intervention.
Antibodies against co-stimulatory and co-receptor molecules T-cells recognize "antigen" as peptides originating from the processing of intracellular (presented by class-I MHC molecules) or from membranous and internalized exogenous structures (presented by class-Il MHC molecules). Optimal T-cell receptor interaction with the HLA/peptide complex (direct or indirect presentation of graft antigens) requires, however, the presence of other families of molecules [see 66 for review]. These families include co-receptor molecules, CD4 and CD8, which bind to different domains of class II and on an epitope of the 3 region of class I, respectively; adhesion molecules (such as LFA-1); and "second signal" molecules, such as CD28 or CTLA-4 [67] . All these molecules interact with their corresponding specific ligands at the membrane of presenting cells (MHC, ICAMs, and B7, respectively). Their presence can result in a restricted recognition (CD4 for class-Il, and CD8 for class-I presentation, for instance), in increased cell/cell adhesiveness and avidity (LFA-1, for instance), and in the production of transcription factors for a variety of cytokines. These cytokines in turn will further induce a self and paracrine promotion of genetically committed T-lymphocytes, as for instance after interaction between B7 and CD8-CTLA-4 [67] . Other molecules are more specialized in T-helper-B-cell interactions, such as CD5 (on T-helper cells), which interacts with CD72, a specific B-cell ligand [50] . However, since the engagement of both co-receptors and adhesion molecules with their ligands have been shown to deliver co-stimulatory signals per se, and since "second signal molecules" such as CD28 do require cell/cell contact for transcriptional activation, the restricted terminology commonly used oversimplifies their dual effect, adhesion as well as stimulation.
The understanding of the various steps controlling T-cell activation opened new possibilities for immuno-intervention through the use of specific inhibitory monoclonal antibodies. Indeed, an antigen-presenting cell that does not express one of these molecules or that interacts with committed T-cells in the presence of a blocking antibody (which interferes with one of these receptor! ligand couples) will not optimally present antigen. In addition, new molecular tools such as truncated receptors or ligands (soluble CTLA-4 or ICAM-1, for instance) fused (or not) with the constant part of an IgG heavy chain have been successfully used and thus may represent alternatives to monoclonal antibodies [68] . But although the possibility of interfering with immune responses through the inhibition of accessory molecules has been actively explored in animals, only anti-CD4 has been used in clinical trials.
During antigen recognition by T-cell receptor, CD4 molecules on T-cells bind class-Il molecules on presenting cells, increasing cell/cell interactions and delivering co-stimulatory signals. CD4 is a monomeric 55 kD glycoprotein that can associate with the 56K (a tyrosine protein kinase [69] ); antibody-mediated crosslinking of CD4 results in increased tyrosine phosphorylation and kinase activity of P56LcK controlled by CD45 [70}. Engagement of CD4 before T-cell receptor cross-linking also can result in cell death by apoptosis. Several CD4 mAbs are available in various species. Encouraging results have emerged from their use in manipulating models of experimental organ transplantation in rodents and primates. In rodents, anti-CD4 mAbs given before grafting induced a state of donor-specific unresponsiveness [see 17
for review]. Second grafts from the same donor strain were prolonged, whereas acute rejection of a third-party graft was observed [71, 72] . Concomitant injection of soluble antigen and anti-CD4 mAb [or F(ab')2 fragments] results in a specific, longlasting unresponsiveness to subsequent initial antigen challenges [73] . As donor-specific blood transfusions can also induce specific hyporesponsiveness to a subsequent organ allograft, combined treatment with donor antigen and anti-CD4 niAbs administered several weeks before transplantation has resulted in an indefinite acceptance of allografts in mice [17] . Induction of the unresponsiveness state was accomplished only at optimal donor-blood transfusion volume and mAb dosage. In this model, F(ab') fragments given at a high dose (times tenfold) also were effective, whereas perioperative injections of the mAbs were less effective than when administered weeks before grafting [17] . The mechanisms responsible for the tolerance induced by anti-CD4 mAbs remain unclear. More information is required regarding the relevance of various epitopes at the CD4 molecule recognized by the mAbs [74] , as well as that of the depleting and/or modulating capacity of a given mAb. After administration of a large dose of a depleting antibody, the tolerance state that follows the nonspecific immunosuppression might result from the emergence of T-cells that have matured in a new environment (that is, in the presence of graft antigens), thus resulting in specific inactivation of a T-cell clone against the alloantigens. Furthermore, CD4 splenocytes from tolerant mice administered with an anti-CD4 mAb actively transfer the specific unresponsiveness state to naïve syngeneic animals [75] . Anti-CD4 mAbs also have been reported to be poorly immunogenic; this finding suggests that they could induce self-tolerance [58] .
Post-graft treatment by OKT4A or a mixture of two anti-CD4 mAbs (OKT4 and OKT4A) in rhesus monkeys prolongs renal graft survival [76] . Several preliminary reports in humans have appeared; the first study used BL4 antibody (IgG2a) administered from day 3 to 14 after transplantation [77] . Although this series was too small to allow any definitive conclusions regarding BL4's effect on early rejection (4 episodes in 12 patients), only one patient developed anti-BL4 antibodies; some anti-CD4 antibodies probably thus can mimic in humans what has been observed in mice [58] . A non-depleting, non-modulating IgG2a, OKT4A was used prophylactically (8-12 days at 0.2 mg/kg/day) in 6 patients, along with a triple induction protocol. Although all patients experienced acute rejection within 6 weeks (3 during OKT4A treatment), no firm conclusion can be drawn because the dosage and timing of OKT4A were not pharmacokinetically optimal [78] . Interestingly, whereas this dose of the mAb was highly immunogenic in humans, a humanized chimeric OKT4A (IgG4) triggers no reactivity in non-human primates [79] .
We have just completed a study of a murine IgGl directed against the second domain of CD4; the antibody was administered in 14 patients for 10 days after renal transplantation (unpublished observations). This mAb transiently depletes CD4 cells and modulates CD4 molecules at the cell membrane. The mAb was not associated with any anti-CD3-like side effects and did not produce a tolerance state; 4 patients experienced acute interstitial rejection shortly after cessation of the mAb. Thus, although the use of blocking, or transiently depleting, anti-CD4 might be somewhat effective and possibly introduces a level of specificity in the treatment of graft recipients, preliminary experience does not suggest that tolerance is achieved in monkeys or humans following anti-CD4 administration. The data are far from conclusive, however. For instance, clinical trials are restricted to administration of anti-CD4 shortly after transplantation or immediately postoperatively; these conditions favor nonspecific immunosuppression rather than specific tolerance. In experimental animals, donorspecific suppression occurs only several weeks or months after anti-CD4 administration [17] .
In addition, immuno-intervention through CD4 manipulation is confounded by hazards inherent to the complexity of mechanisms of the CD4-mediated effect in allorecognition. First, the respective involvement of CD4 versus CD8 populations depends highly on the expression of either class-I or -II MHC molecules on the graft, the pre-immunized or naïve status of the recipients, and the kinds of grafted tissue; inhibition of the CD4 subset thus might not always be adequate. Our current understanding of the mechanisms of action of anti-CD4 is probably simplistic. We perceive a decrease in the affinity of the CD4 cell in immune interaction that results from the administration of blocking, modulating, or depleting anti-CD4, and a subsequent impairment in helper T-cell function. But peripheral blood depletion is not always associated with a significant lymph node or thymic depletion [17] . Furthermore, in mice treated by an anti-CD4, a peripheral anergy has been evidenced in alloreactive cells identified by monoclonal antibodies (V5 Vf31 1k) ; however, the co-administration of anti-CD8 prevented the development of anergy of V135 V/311 cells without blocking the tolerance against the allogeneic islet cells used in this model [80] . Also, helper memory cells and the TH2 population producing IL1O and 1L4 escape anti-CD4 therapy in rodents [81] , whereas only few 1L2-producing cells were found. This profile suggests an imbalance in TH1/TH2 reminiscent of that reported in donor-cell-injected cardiac graft recipients [82] . Although CD4 manipulation is extremely promising, we need to further understand its mechanism of action and its role in the treatment of patients undergoing renal transplantation.
Monoclonal antibodies against interleukin 2 receptors
The availability of antibodies directed at activation determinants induced on the genetically pre-committed lymphocyte subset, such as mAbs targeting 1L2-receptor (IL2R), offers a new possibility for more selective immunosuppression. Resting T-cells neither express the a(P55) low-affinity component of IL2R nor the functional high-affinity IL2R. Following antigenic stimulation through the T-cell receptor, specific T-lymphocytes are activated, 1L2 is secreted, and functional IL2R is transiently expressed [83] ; this process allows antigen-committed lymphocytes to expand. At least three polypeptide chains contribute to the formation of the functional IL2R. The a or Tac chain was the first component recognized; this 55 kD glycoprotein is the antigen-inducible structure of the system and, after antigenic stimulation, its expression increases by at least 10 times. This chain alone has a low affinity for 1L2 (Kd 20 nM) [83] and is not able to internalize 1L2 [84] . The 75 kD J3 chain has an intermediate affinity for 1L2 and is required to internalize 1L2. The 13 chain, needed to optimize signal transduction, is also present on resting T-lymphocytes and natural killer cells. After antigenic a chain induction, approximately 10% of a chains associate with the 13 chain and form the high-affinity IL2R (lCd 30 pM) [85] in the presence of a third component, the recently characterized gamma chain [86] . The gamma chain is involved in the high-affinity conformation as well as in the signal transduction; specific mutations of this gamma chain, which is shared by 1L4 and 1L7 receptors [87] , result in severe congenital immunodeficiency in humans [88] .
As P55 contributes to the high-affinity complex, mAbs directed at the 1L2-binding site of the a chain are potent inhibitors of 1L2-driven proliferation. Their presence, in sufficient amounts to block 1L2-binding, therefore should result in the specific inhibition of the growth of the pre-committed recipient cells activated by foreign antigens. Theoretically, this approach spares the resting T-cell repertoire. But the recipient's immune response against any other T-cell-dependent antigens introduced into the recipient during anti-IL2R treatment also will be depressed. Interleukin 2 has been well documented as a major pivotal growth factor for T-lymphocytes; however, it is likely that other lymphokines can substitute for 1L2. Verification comes from studies of animals in which the 1L2 gene has been disrupted by homologous recombination [89] and which can still mount some T-cell response. Both 1L4 and 1L7 are potent T-cell growth factors that can partially replace 1L2. However, antibodies directed against IL2R are highly effective in a variety of animal models and in humans. In the mouse, treatment for only 10 days produces indefinite graft survival in more than 50% of recipients [90] . In the rat, anti-IL2R antibodies are effective as single agents and also act in synergy with cyclosporine [91] . A mice anti-human a chain of IL2R
(anti-Tac) allows the prolongation of renal allografts in cynomolgus monkeys [92] .
We have used a rat IgG2a mAb (33B3.1), which inhibits IL2 binding on both P55 and high-affinity IL2R, and which blocks IL2-driven proliferation [93, 94] , to determine its effect in kidney transplant recipients [95] . To date, we have given this mAb to 135 recipients of first or second renal or renal/pancreas transplants. Almost all recipients tolerated the 33B3.1 well. Although a dose of 5 mg/day was insufficient to obtain "therapeutic" trough levels, 10 mg/day produced a trough level of approximately 4 sg/ml and gave encouraging results in a preliminary study on the prevention of acute rejection episodes [95] . We gave the mAb immediately after transplantation and for 2 weeks thereafter along with corticosteroids and azathioprine.
We subsequently conducted a prospective, randomized, controlled trial [96] . One hundred consecutive recipients of primary cadaveric renal transplants received either 33B3.1 (n = 50) or a rabbit ALG (n = 50). The 33B3.1 was given at 10 mg/day in the first 2 weeks after surgery with 1 mg/kg of methylprednisolone and 2 mg/kg of azathioprine; at the end of the mAb course (day 14), CsA was started. Only one patient treated with 33B3.1 required that the drug be stopped because of major clinical intolerance, versus 16 (32%) patients in the ATG group. A similar number of rejection episodes occurred during the first 3 months (15 versus 12 in the 33B3.1 and ALG groups, respectively). However, the 33B3.1-treated recipients experienced more rejection episodes during the first 2 weeks (6 versus 1). Between months 4 and 12 after transplantation, 7 patients in the ALG-treated group experienced a total of 9 rejection episodes versus 3 patients with 3 rejection episodes in the mAb group (NS). After the first year, the incidence of rejection episodes was 5% in both groups of patients. Fewer episodes of infectious disease occurred in the 33B3. 1 group (47 versus 72); possibly the activated T-cell specificity produced more specific immunosuppression. Regarding viral infections (in which T and NK cells have been mostly involved), 8 of the 9 cases of cytomegalovirus disease in the mAb group were mild, while half (5 of 10) were severe in the ALG-treated group. After three months, the number of infectious episodes remained lower in patients who received the mAb as compared with those treated with ALG (9 versus 23). A strong immunization against rat IgG2a occurred in 80% of patients receiving 33B3.1, thus significantly lowering circulating mAb levels.
Less-favorable results have been obtained in two additional studies conducted in repeat renal transplantation [97] and in simultaneous renal/pancreatic transplantation [98] . In second renal transplant recipients, 33B3.1 was given for the first 10 postoperative days in association with steroids and azathioprine (CsA was started at day 10). Similar patient and graft survival rates were observed at one year (77% versus 71% in ALG and 33B3.1), and an equal incidence of rejection episodes occurred with both regimens (45% and 44%). Rejection was more frequent (40% versus 0% in the ALU group) during the 10 days of therapy with the monoclonal antibody, however, despite high circulating trough levels. Almost all recipients were sensitized by 33B3.1. In double graft recipients, CSA was associated with 33B3.1 for the first 10 days. No rejection occurred during the 10 days of treatment in these patients. Later, episodes of kidney rejection were more frequent in the 33B3.1-treated patients. All these diabetic recipients had received grafts without tissue matching. Patient survival was 83% and 100% in the ATG and 33B3.1 groups, respectively.
Because the 33B3.1 was effective in preventing rejection episodes and anti-IL2R could reverse ongoing rejection in animals, we initiated a pilot study to assess the effect of this mAb in the treatment of 10 initial, acute interstitial rejection episodes in first kidney grafts [5] . Six episodes partially responded to treatment and 4 required rescue treatment. During ongoing rejection episodes, the effector T-cells had already proliferated, expanded within the transplant, and recruited inflammatory cells. At that time the effector mechanisms resulting in rejection are no longer restricted to activated T-lymphocytes, which are the primary targets of anti-IL2R.
Other clinical trials have been performed following renal transplantation with different anti-P55 mAbs, Kirkman and colleagues reported a randomized trial of anti-Tac (murine IgG2a against P55 chain) in human renal transplantation [99] . As we did, they gave anti-Tac mAb as induction therapy along with steroids and azathioprine, but CsA also was added. Their results suggest that anti-Tac decreases early (first month) rejection episodes in renal allografts. Other studies have shown the efficacy of a rat mAb, IgG2b (LO-Tac-1), and a mouse IgGi mAb (BT563), in renal and liver transplantation [100, 101] . The literature appears to confirm that blocking 1L2 binding results in successful allotransplantation. But it is too early for us to conclude that this approach also will be beneficial in transplants performed in hyperimmunized patients or on second grafts. The availability of "humanized" mAb [102] , and the use of mAb combinations [103] or bispecific mAb [104] might further enhance the efficiency of anti-IL2R. Nevertheless, anti-IL2R currently is probably the most promising bioreagent in prophylactic therapy for first-kidney grafts, owing to its absence of side effects and higher specificity.
Antibodies directed against cytokines themselves also have been tested in animals. The theoretical advantage of such an approach would be high biologic specificity; however, the local range of activity of most of the cytokines, and the stoichiometnc ratio of ligand/receptor, might explain the dearth of reports.
Other targets, monoclonal antibody combinations, and engineered reagents A variety of monoclonal antibodies directed at epitopes present on resting or activated T-cells-or with wider distribution-also has been used experimentally and sometimes clinically. These mAbs belong to a heterogeneous group including anti-CD52, anti-CD45, and antibodies directed against yet-unknown specificities.
Campath-1. The family of Campath-1 antibodies comprises rat mAbs of various isotypes, including 1gM as well as a chimeric human IgG. These mAbs recognize a phosphatidylinositolanchored antigen (CD52) expressed on virtually all white blood cell lineages [105] . Campath-1 binds human complement [106] and effectively purges bone marrow of T-cells through humancomplement-mediated cytotoxicity. Campath-1 has been evaluated further in a randomized trial in 52 renal allografts [107] . The protocol compared Campath-1 (25 mg/day for 10 days) and high doses of CsA (17 mg/kg) with high doses of CsA alone. The incidence of rejection episodes was lower in the mAb group; however, major infection episodes significantly increased after mAb treatment. The anti-rat immunoglobulin antibodies, detectable on day 10, further increased during the following 7 days.
Other 1gM inAbs. Although the use of Campath-1 seems attractive when compared with polyclonal anti-lymphocyte globulins, this approach carries the risk of over-immunosuppression, a problem difficult to assess because the mAb was administered with high doses of CsA [106] . The effectiveness of this monoclonal antibody is likely related to its capacity to bind human complement. Thus 1gM mAbs probably act more via their isotype-linked properties rather than by interacting with a molecule exclusively involved in alloimmune recognition. Accordingly, several groups have followed the same approach of using a monoclonal antibody of the 1gM isotype in an attempt to increase effector function. Takahashi et al first used the CBL1 mAb (a mouse 1gM) directed against a determinant present on human lymphoblast cells [13] . They administered the CBL1 mAb at 5 mg/day for 9 days in acute steroid-resistant rejection episodes.
The mAb was beneficial in 50% to 90% of the episodes [108] .
Despite these promising initial studies, results concerning prophylactic utilization of CBL1 in allograft recipients of living-related kidneys were inconclusive [109] .
Another 1gM, the CHAL 1 monoclonal antibody (anti-T and -B cells and anti-monocytes), was tested at 12 to 24 mg daily doses over 9 days in 28 renal graft recipients undergoing acute corticosteroid-resistant rejection episodes (4 living-related grafts, 18 first, and 6 second cadaveric grafts) [108] . Fourteen cadaveric graft recipients received CsA and prednisone; the others received prednisone and azathioprine. The reversal rate was higher among CsA-treated patients than among azathioprine-treated patients (81% versus 50%), but 33% of the patients treated with CHAL1 had rejection recurrence in this preliminary report [108] .
Anti-CD45. Also of 1gM isotype, this monoclonal antibody has been used to eliminate passenger leukocytes within allografts, particularly the interstitial cells of bone marrow origin, which are believed to play a major role in the "direct" pathway of presentation of donor-specific antigens to the recipient lymphocytes. This mAb is directed against a widely expressed CD45 isoform present on almost every white blood cell lineage (a protein tyrosine phosphatase that is produced as additional forms from a single gene by alternate splicing). Ex vivo, anti-CD45 treatment of renal grafts produces a high degree of coating of CD45 cells and significantly decreases the incidence of subsequent rejection (18% versus 63%) [110] . The availability of a monoclonal anti-pig CD45 has allowed the same group to better assess the ex-vivo perfusion conditions and reach a CD45 labeling rate of at least 95%. Anti-CD7 mAb. Anti-CD7 monoclonal antibodies recognize a 40 kD antigen present on T-cells and preferentially on T-cell blasts [111] . A chimeric anti-CD7 mAb derived from the RFT2 hybridoma [9] has been studied as a prophylactic regimen in renal allograft patients. The mAb was well tolerated, induced a modulation of the CD7 molecule, and did not trigger anti-mAb host antibodies. Further, the mAb's ability to prevent early rejection was encouraging [10] . Monoclonal antibody combinations and bifunctional antibodies. Although combinations of mAbs recognizing synergistically active molecules have been shown to be more potent in inhibiting some immunologic functions in vitro than when used alone, in-vivo experiments have been limited so far. In recipients of mismatched bone marrow, a slight beneficial effect on rejection was observed in patients receiving anti-LFA-1 and an anti-CD2 (Fisher A, personal communication). The combination of anti-LFA-1 and anti-CD2 has proved highly effective in inhibiting mixed lymphocyte response (MRL) in vitro (BOhmig GA, personal communication). There are, in addition, several other examples in which combinations of two mAbs are attractive. For instance, 33B3.1 antibody cannot block 100% of 1L2-(or mitogen)-induced proliferation of alloreactive clone in vitro, whereas when 33B3.1 is combined with a second mAb directed to IL2R 13 chain, the proliferation of the 1L2-induced clone, as well as 1L2 binding, are almost completely inhibited [103] . This finding suggests that the combination would increase the effectiveness of anti-IL2R therapy. Interestingly, it is the combination of two antibodies directed at epitopes carried by independent targets such as ICAM and CD11a [16] or CD2 and CD3 [65] that has been able to achieve tolerance in animals, whereas the administration of a single mAb was ineffective.
Another way of combining the effect of two mAbs displaying potentially synergistic functions is preparing bispeeifie antibodies. Keeping with the IL2R targeting example, bispeeifie antibodies carrying both anti-P55 and anti-P75 specificities are highly efficient in inhibiting 1L2 binding and IL2-dependent proliferation in vitro [104] . Although it is difficult to conceive that clinicians will soon have the opportunity to demonstrate as clinically valuable all the theoretical possibilities of intervention using mAbs, bifunctional antibodies also could be used to increase the targeting efficacy to a given molecule if one of the specificities is devoted to CD3 recognition [112] . This dual recognition will result in the killing of cells that have been brought into the CD3 + cell vicinity by the second specificity of the bifunctional killing.
Conclusion
Although only partially explored in animals and having restricted application in humans so far, the use of monoelonal antibodies in transplantation has opened up a large field of new possibilities. However, the high clinical cost of this approach will no doubt limit the study of many mAbs. In many instances (for example, anti-CD4) different results may arise from the use of antibodies that recognize distinct epitopes on the same molecule; this situation will render unpredictable the effect of some mAbs in humans. Furthermore, some degree of the species specificity in the immune response (as well as variations in the pattern of target distribution between humans and animals) can make even more difficult the extrapolation of the usefulness of an antibody active in animals to the clinical setting. Finally, the paradigm of an exclusively specific intervention on the immune system is tempered in practice by the role of the constant parts of the antibodies-and of their corresponding isotypes-that will be even more important in "humanized" reagents. Indeed, "optimal" constant part-related effector functions (for example, complement-fixing isotypes) can result in cell destruction with a decreased specificity of action. Therefore, working hypotheses based on specific targeting of key molecules at the membrane of immunocompetent cells might be fundamentally biased except for targets expressed on highly restricted cell subsets (such as the 1L2 receptor). For target molecules more widely expressed, effector mechanisms aimed at a specific intervention should work through membrane modulation of the molecule or specific competition with the corresponding ligands. Although molecular engineering of the mAb can favor either alternative-strict molecular target specificity by the use of scFv fragments for instance [47] , or "optimal" constant region by the choice of the adequate isotypethe final relevance of the "target effect" still depends on all these factors.
Questions and answers DR. NIcoLAos E. MADIA5 (Chief Division of Nephrology, New England Medical Center, Boston, Massachusetts): What is the best available explanation for the marked release of cytokines after OKT3 administration but not after treatment with other anti-Tcell mAbs? Is it a difference in cytolysis or in T-cell activation? DR. SouLILLou: It seems that the magnitude of the side effect in vivo correlates with the proliferative signal delivered in vitro by the anti-CD3. The differences likely are due to the isotypes of the mAb that control Fe-related functions. The in-vivo side effect will then depend on the capacity of the mAb to bridge the monocytes and macrophages that activate T-eells. Some recipients have fewer side effects than do others because they express Fe-receptor polymorphism. Some Fc species do not interact with Igi or Ig2b mAb for instance [113] . In this last case the magnitude of side Administration of an anti-ICAM-1 antibody to rats at the time of ischemia or even 2 hours after the isehemie period resulted in marked functional and morphologic protection [114] . DR. SouLILLou: Cosimi's group recently reported a preliminary study in Transplantation suggesting that anti-ICAM-1 prevents delayed graft function of transplants stored at 4°C for more than 48 hours [61] . However, only few patients with high enough anti-ICAM-1 trough levels were studied, and these results need confirmation. If this protective effect is related to the inhibition of leukocyte adhesion to isehemic endothelial cells by interfering with the ICAM-1/LFA-1 interaction, then blocking of LFA-1
should be even more effective because more ligands (ICAM-2, -3, and unknown) should be involved. As in our pilot study with the anti-CD11a, cold ischemia time longer than 48 hours was an exclusion criterion, and we have to wait for the result of a currently running randomized study to assess the effect of the inhibition of LFA-1/ICAM interactions on delayed graft function. However, several reports now indicate that administration of soluble sugars, which are the ligands of selectin involved in the first step of the interaction of leukoeytes with endothelial cells, is effective in decreasing the inflammatory lesions on tissue microvasculature [52] . Similarily, inhibition of IL-8, which also indirectly controls the adhession process, decreases the reperfusion syndrome [115] . Inhibition of LFA-1/ICAM-1 interaction, which comes later in this cascade, is probably also effective. I am personally convinced that the inhibition of adhesion molecules (integrins, L, E, or P selectins) or their ligands will be important in the future. DR. SOULILLOU: Anti-thymocyte globulin contains antibodies against a variety of targets [116] . However, I know of no evidence for attributing its effect to a single specificity. In this respect it is possible to consider ATG a "cocktail" of various mAbs.
The second part of your question relates to the monitoring of the effects of such bioreagents. Clearly, one cannot monitor accurately all the effects of ATG, although some of its effect-for instance, inhibition of AETTcell rosetting-is of great practical importance [117] . My second question relates to the immunologic phenomenon denoted by the term "modulation," that is, endocytosis of cellsurface markers. Although modulation of CD3 secondary to OKT3 has been documented [27, 28], it does not appear to be of clinical significance because T-cells without CD3 are immunologically ineffective. However, does anti-CD4 therapy cause modulation of the CD4 molecule? Furthermore, could the limited benefit of anti-CD4 therapy be related to modulation? DR. SOULILLOU: Dr. Brenner's hypothesis is attractive, although I think that "in addition to" would be wiser than "rather than," because there is a large body of information on the importance of immune mechanisms in chronic rejection; for instance, fully matched kidneys have less frequent chronic rejection. The precise immunologic mechanisms of chronic rejection and their relevant targets are yet totally unknown. However, decreasing the incidence of early acute rejection by an efficient prophylactic treatment might be a way of decreasing the incidence of chronic rejection.
Regarding your question on modulation, I do not agree that the CD3 modulation is not a relevant test because CD3 -cells are "immunologically ineffective." Indeed, it is that test that tells you that CD3 has been modulated. It seems to me that a test that tells us that T-cell function is impaired during OKT3 treatment is important in many circumstances, particularly when neutralizing antibodies are suspected. However, better information could come from analysis of cells infiltrating that graft during anti-CD3 treatment.
Regarding the anti-CD4 effect, some anti-CD4 mAbs cause modulation, but not all. That the effectiveness of an anti-CD4 correlates with its capacity to modulate anti-CD4 at the lymphocyte membrane would appear logical. However, K. Wood, of Oxford, presented preliminary evidence at the September 1993 Basic Science Symposium in Transplantation that, in the murine model, the capacity of CD4 modulation of an anti-CD4 mAb might not be an advantage for induction of tolerance, but rather that modulation might be a "defense" mechanism in this particular case, More information is needed. Regarding the second part of your question, in anti-IL2R treatment, no circulating mAb was found 1 to 2 days after cessation of treatment. In patients who had received anti-CD11a, the circulating mAb was present much longer; in fact, significant trough levels were observed between days 4 and 10 after the end of the treatment. 
